Medical Oncology

, Volume 28, Issue 3, pp 813–821

Anti-cancer effects of 20(S)-protopanoxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4;11

  • Lihua Sun
  • Qiong Wang
  • Xinmin Liu
  • Nicolaas H. C. Brons
  • Ning Wang
  • André Steinmetz
  • Yali Lv
  • Yonghong Liao
  • Huyong Zheng
Article

DOI: 10.1007/s12032-010-9508-1

Cite this article as:
Sun, L., Wang, Q., Liu, X. et al. Med Oncol (2011) 28: 813. doi:10.1007/s12032-010-9508-1
  • 203 Downloads

Abstract

Although the treatment outcome of acute lymphoblastic leukemia (ALL) has been improved in the past decades by combination chemotherapy, toxic side-effects of chemotherapeutics remain a major problem. Therefore, new alternative agents with low toxicity are urgently needed. Natural products provide a rich source of screening potential anti-cancer drugs. 20(S)-protopanoxadiol (PPD), a major gastrointestinal metabolic product of ginsenosides, exhibits promising anti-cancer activity with low toxicity. However, the anti-cancer activity of PPD against ALL has not been evaluated. In this study, we examined the anti-cancer effect of PPD on ALL cell lines Reh and RS4;11. The growth of leukemia cells and normal cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cell cycle, apoptosis and differentiation was determined by flow cytometry. The results showed that PPD inhibited the growth of Reh and RS4;11 cells, but had little toxicity to peripheral blood mononuclear cells (PBMC). PPD also blocked cell cycle progression from G0/G1 phase and induced cell differentiation. However, cell apoptosis was not affected. These data indicate that PPD exerts anti-cancer effects by stimulating differentiation and inhibiting growth and cell cycle progression of ALL cells.

Keywords

20(S)-protopanoxadiol (PPD)Acute lymphoblastic leukemia (ALL)IC50Cell cycleDifferentiation

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Lihua Sun
    • 1
  • Qiong Wang
    • 1
  • Xinmin Liu
    • 1
  • Nicolaas H. C. Brons
    • 2
  • Ning Wang
    • 3
  • André Steinmetz
    • 3
  • Yali Lv
    • 1
  • Yonghong Liao
    • 1
  • Huyong Zheng
    • 4
  1. 1.Research Center for Pharmacology & Toxicology, Institute of Medicinal Plant Development (IMPLAD)Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingPeople’s Republic of China
  2. 2.Core Facility FlowcytometryCentre de Recherche Public de la Santé (CRP-Santé)LuxembourgLuxembourg
  3. 3.Department of Virology, Allergology and ImmunityCentre de Recherche Public de la Santé (CRP-Santé)LuxembourgLuxembourg
  4. 4.Department of HematologyBeijing Children’s Hospital, Capital University of Medical SciencesBeijingPeople’s Republic of China